The subthalamic nucleus (STN) is a small, excitatory nucleus that regulates the output of basal ganglia motor circuits. The functions of the STN and its role in the pathophysiology of Parkinson’s disease are now well established. However, some basic characteristics like the developmental origin and molecular phenotype of neuronal subpopulations are still being debated. The classical model of forebrain development attributed the origin of STN within the diencephalon. Recent studies of gene expression patterns exposed shortcomings of the classical model. To accommodate these findings, the prosomeric model was developed. In this concept, STN develops within the hypothalamic primordium, which is no longer a part of the diencephalic primordium. This concept is further supported by the expression patterns of many transcription factors. It is interesting to note that many transcription factors involved in the development of the STN are also involved in the pathogenesis of neurodevelopmental disorders. Thus, the study of neurodevelopmental disorders could provide us with valuable information on the roles of these transcription factors in the development and maintenance of STN phenotype. In this review, we summarize historical theories about the developmental origin of the STN and interpret the gene expression data within the prosomeric conceptual framework. Finally, we discuss the importance of neurodevelopmental disorders for the development of the STN and its potential role in the pathophysiology of neurodevelopmental disorders.
Asparagine synthetase deficiency (ASNSD) is a rare metabolic disease causing congenital microcephaly, severe developmental delay, and spastic quadriplegia. Although the central nervous system is severely affected, other organ systems appear unaffected by asparagine deficiency. We present an infant homozygous for the mutation c.904‐1G>A in the ASNS gene, whose clinical presentation and radiological findings were typical for ASNSD. Following the patient's death at the age of 6 months, histological and immunohistochemical examination of the telencephalon revealed a vast disturbance of migration of neuronal subpopulations, consequently severe disorganization of cortical layers, and thinning of the cerebral cortex. These findings provide novel insights into disease pathogenesis and may explain the hallmark features of ASNSD, including microcephaly and epilepsy.
Commercial antibodies show variable specificity and performance, limiting reproducibility of immunohistochemical studies. We systematically evaluated antibodies used to detect brain proteins across species. Established Western blotting (WB) and immunofluorescence (IF) validation approaches were applied systematically and in parallel to mouse, rat, and human brain tissue. The distinctive scope of the study was the comparative evaluation of 23 antibodies targeting 17 proteins, with WB results interpreted in the context of expected molecular weights, isoforms, post-translational modifications, and published evidence concerning each target. Antibody performance was further compared with publicly available validation information, and logistic regression was used to assess whether antibody citation count and manufacturer-provided validation information predicted successful experimental validation. Ten antibodies (43%) showed supportive WB results, and eight (35%) were validated by both WB and IF. Several antibodies produced unexplained or non-specific bands, while others showed speciesdependent performance. Validated antibodies displayed appropriate neuroanatomical and subcellular staining patterns. Antibody citation count was moderately associated with successful validation, whereas manufacturer-provided validation information did not improve predictive performance. The overall validation rate was comparable to previously published antibody validation studies and Human Protein Atlas results. The present study extends existing work through its broader antibody panel, parallel cross-species evaluation, detailed target-protein assessment, and quantitative analysis of antibody metadata. Commercial antibodies require independent validation before use in cross-species immunohistochemical studies. Our results provide a practical resource for antibody selection and highlight limitations of manufacturer claims and citation counts as indicators of antibody performance.